EXEL News and Press, Exelixis Inc. From 08/09/22

Exelixis, Inc. (EXEL) Q2 2022 Earnings Conference Call August 09, 2022, 17:00 ET Company Participants Susan Hubbard - EVP, Public Affairs & IR Michael Morrissey - CEO, President & Director Christopher Senner - EVP & CFO Patrick Haley - EVP, Commer...

Exelixis press release ( NASDAQ: EXEL ): Q2 Non-GAAP EPS of $0.28 beats by $0.04 . Revenue of $419.43M (+8.9% Y/Y) beats by $26.42M . Cash, cash equivalents, restricted cash equivalents and investments were $2.0 billion at June 30, 2022, compared to $1.9 billio...

- Total Revenues of $419.4 million, Cabozantinib Franchise Revenues of $347.0 million - - GAAP Diluted EPS of $0.22, Non-GAAP Diluted EPS of $0.28 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today reported fin...

It's hard to sugarcoat the current state of equity markets and the broader economy. Things don't look good. Inflation, a potential recession on the way, geopolitical tensions, and supply chain issues are just some of the challenges we face. With all that going on, it might be tempting to gi...

Cabo is a blockbuster drug, but there are potential headwinds. EXEL needs to find other assets and move them to late stages. With XL092, Exelixis is starting to do just that. The trouble with Exelixis ( EXEL ) is that while it is spending $650mn annually running vari...

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022 after the markets close. At 5:00 p.m. ET / 2:00...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With fears of a global recession rising, it’s natural that investors have turned their back on growth-intensive names. However, this backdrop has also yielded compelling undervalued biotech stocks to buy. While very ...

Exelixis (NASDAQ: EXEL) and CRISPR Therapeutics (NASDAQ: CRSP) have been able to parlay their specialized knowledge of genetic therapies into share-price growth. While the Fidelity Select Biotech ETF is down more than 22% for the year, these two biotechs have been able t...

Biotech company Exelixis (NASDAQ: EXEL) is not the most famous name in the industry. But quietly, the oncology-focused drugmaker has provided excellent returns this year, even though it's been a bit of a roller-coaster ride. If Exelixis can continue beating the market, investors...

Exelixis ( NASDAQ: EXEL ) is accusing MSN Pharmacueticals of patent infringement over its Abbreviated New Drug Application to market a generic of Cabometyx (cabozantinib). The lawsuit was filed Monday in a Delaware federal court. Exelixis is assert infringement of ...